Overview
The fund is passively managed and is distinguished by broad diversification, low tracking errors, and low-cost management.
The investment objective is to replicate the reference index as closely as possible and to minimize performance deviations from the benchmark.
The MSCI World ex Switzerland Index captures large and mid cap representation across Developed Markets countries worldwide (excluding Switzerland).
The index covers approximately 85% of the free float-adjusted market capitalization in the World ex Switzerland equity universe.
Benefits
Easy access to a broadly diversified portfolio of World ex Switzerland Equities.
Provides access to the performance of the index with a single transaction.
The fund is transparent and cost-effective and is liquid under normal market conditions.
You do not pay any federal stamp duty.
Risks
Features
| Product category |
Equity Global |
| Product domicile |
Switzerland
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS Fund Management (Switzerland) AG
|
| Custodian bank |
UBS Switzerland AG, Zurich
|
| Day of inception |
August 7, 2014
|
| Currency of account |
CHF
|
| Close of financial year |
February 28
|
| SFDR Classification |
n.a.
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.21% p.a.
|
| Flat fee |
0.10% p.a.
|
| Total expense ratio (TER) |
0.21% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI World ex Switzerland (NR) in CHF
|
| Cut-Off Time |
15:00h(CET)
|
| Securities no. |
4280055
|
| ISIN |
CH0042800554
|
| Bloomberg Ticker |
CSWEXIF SW
|
| Reuters Id |
4280055X.CHE
|
Performance and Prices
Percentage growth
as of April 23, 2026| CHF(%) | EUR(%) | USD(%) | |
| YTD | 3.44 | 4.87 | 4.58 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 5.62 | 6.53 | 20.82 |
| 3Y | |||
| 5Y | 44.47 | 73.92 | 69.04 |
| ø p.a.5Y | 7.64 | 11.70 | 11.07 |
Current data
| Net asset value | 23.04.2026 | CHF 2,663.01 |
| High - last 12 months | 22.04.2026 | CHF 2,671.23 |
| Low - last 12 months | 24.04.2025 | CHF 2,166.52 |
| Assets of the unit class in mn | 23.04.2026 | CHF 117.33 |
| Total product assets in mn | 23.04.2026 | CHF 2,353.95 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 10.81% | 13.17% |
| Sharpe Ratio | 31.03.2026 | 0.56 | 0.49 |
| Risk Free Rate | 31.03.2026 | 0.46% | 0.40% |
Structures
By the 10 largest positions (in %, as of March 31, 2026)
|
|
|
| UBS MSCI USA NSL UCITS ETF | 62.86 |
| UBS CH INDX-EQU USA NSL-IXAC | 10.09 |
| UBS MSCI EMU NSL | 9.04 |
| UBS CH FD-EQ JPN NSL-I-X-ACC | 5.87 |
| UBS CH IDX-EQ CANADA NSL-IXA | 3.69 |
| UBS CH IF EQ PAC XJAP NSL IX CHF | 2.76 |
| AstraZeneca PLC | 0.38 |
| HSBC Holdings PLC | 0.35 |
| Shell PLC | 0.34 |
| UBS (CH) Institutional Fund - Equities Israel Index NSL | 0.28 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|||
| Prospectus |
|
|
||
| Key Information Document |
|
|
|
|
| Past performance |
|
|
|
|
| Previous performance scenario |
|
|
|
Document type
|
Document Language
|
|
| Annual report |
|
|